Raymond James Downgrades Disc Medicine (IRON) to Outperform, 'Mixed Outcome as Key Secondaries Miss Due to Large Placebo Response'
Tweet Send to a Friend
(Updated - April 1, 2024 10:53 AM EDT)
Raymond James analyst Danielle Brill downgraded Disc Medicine (NASDAQ: IRON) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Raymond James analyst Danielle Brill downgraded Disc Medicine (NASDAQ: IRON) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
